RecruitingPhase 2NCT07111065
Rare condition
Dermatomyositis
48
studies recruiting now
as of 7 Sept 2026
189
studies registered in total
as of 7 Sept 2026
13
countries with a recruiting site
as of 7 Sept 2026
2 Sept 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNCT00017914
Adult and Juvenile Myositis
RecruitingPhase 2 / Phase 3NCT06154252
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
RecruitingPhase 1 / Phase 2NCT07800871
FT839 in Autoimmune Diseases
RecruitingPhase 3NCT06698796
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 48 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Dermatomyositis study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Dermatomyositis
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Treatments being studied
3 approved treatments and 27 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Prednisone (Cortan)Approved: Cortisone Acetate (Cortate)Approved: Prednisolone (Cortalone)
Phase 3Aldesleukin (Proleukin)
Phase 3Baricitinib (Olumiant)
Phase 3Lenabasum
Phase 3Ustekinumab (Stelara)
Phase 3Human Immunoglobulin G (Flebogamma dif (previously flebogammadif))
Phase 3Brepocitinib
Phase 2/3Etanercept (Benepali)
Phase 2/3Ravulizumab (Ultomiris)
+ 19 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).